


## **Supplementary Material 1**

Cardiovascular outcomes and fracture risk after the discontinuation of preventative medications in older patients with complex health needs: a self-controlled case series analysis



**Figure S1: Self-controlled case series design** Within each patient's follow-up, event rates during exposed (*treatment period*) and unexposed (*post-discontinuation*) time windows are compared.




Figure S2: Study inclusion flowchart for the hospitalisation cohort




Figure S3: Study inclusion flowchart for the frailty cohort






Figure S4: Study inclusion flowchart for the polypharmacy cohort




**Figure S5: Self-controlled case series** in the hospitalisation cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals



**Figure S6: Self-controlled case series** in the frailty cohort.


N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




**Figure S7: Self-controlled case series** in the polypharmacy cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals






**Figure S8: Self-controlled case series** in the complex health needs cohort (CHN).  
N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals




**Figure S9: Self-controlled case series** in the hospitalisation cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals



**Figure S10: Self-controlled case series** in the frailty cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals



**Figure S11: Self-controlled case series** in the polypharmacy cohort.

N(Persons) = Number of persons, N(Events) = Number of events, PY = patient years, IRR = Incidence rate ratio, CI = 95% confidence intervals





Figure S12: Assumption testing for cardiovascular events in CHN cohort. Distribution of number of events relative to treatment end and start for antihypertensives and statins.



**Figure S13: Assumption testing for fractures** in CHN cohort. Distribution of number of events relative to treatment end and start of bisphosphonates.

**Table S1: Follow-up duration in year for people with and without events** in CHN cohort without previous use of respective preventative medication

	1 <sup>st</sup> Qu. [years]	Median [years]	3 <sup>rd</sup> Qu. [years]
<b>Antihypertensives-naïve people</b>			
with MI	3.20	5.24	6.91
without MI	1.81	4.21	5.93
with stroke	2.77	4.78	6.65
without stroke	1.80	4.21	5.93
<b>Bisphosphonate-naïve people</b>			
with fractures	3.44	5.23	6.74
without fractures	1.76	3.99	5.83
<b>Statin-naïve people</b>			
with MI	2.83	4.57	6.28
without MI	1.68	3.81	5.78
with stroke	2.66	4.54	6.28
without stroke	1.68	3.81	5.77

**Table S2: Number of events per person** in CHN cohort without previous use of respective preventative medication.

	Number of events per person					
	1	2	3	4	5	6
<b>Myocardial infarction</b>						
In antihypertensives-naïve people	841	51	<5	<5		
In statin-naïve people	2,021	152	17			
<b>Fractures</b>						
In bisphosphonate-naïve people	15,478	2,565	448	88	22	5
<b>Stroke</b>						
In antihypertensives-naïve people	1,123	104	9	<5		
In statin-naïve people	2,696	247	18	<5		